Reviva Pharmaceuticals Holdings, Inc..
RVPH.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Reviva Pharmaceuticals Holdings, Inc. is a biopharmaceutical company focused on developing therapies for central nervous system (CNS) diseases. The company's lead product candidate, Brilaroxazine, is being developed for the treatment of schizophrenia, bipolar disorder, and other CNS disorders. Reviv...Show More
Better Health for All
0
Reviva Pharmaceuticals' core business is dedicated to developing therapies for central nervous system diseases, with its lead product candidate, Brilaroxazine, showing statistically significant and clinically meaningful reductions in schizophrenia symptoms in Phase 3 trials.
1
This indicates exceptional health benefits, aligning with the company's entire business being devoted to health improvement. As the company is in clinical development, it currently has no revenue-generating products, resulting in no harmful revenue share.
2
However, the safety record for Brilaroxazine in the 1-year Phase 3 open-label extension study shows a 35% discontinuation rate and 8.5% of participants reporting at least one treatment-emergent adverse event, with mild weight gain of 1.52 kg observed.
3
While no drug-related serious adverse events were reported, these rates indicate a notable level of user harm.
4
The company's focus on schizophrenia treatment is noted, but no broader mental health initiatives are detailed.
5
The company holds composition of matter patents for its drug candidates in multiple countries, but there is no information regarding patent flexibility or access programs.
6
Fair Money & Economic Opportunity
0
No evidence available to assess Reviva Pharmaceuticals Holdings, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No specific, quantitative data points for RVPH.US relevant to any of the Fair Pay & Worker Respect KPIs were found in the provided articles.
1
The articles discuss general topics like gender wage transparency, pay disparities in healthcare, and the process of pay equity audits, but do not offer company-specific information or metrics for Reviva Pharmaceuticals Holdings, Inc.
2
Fair Trade & Ethical Sourcing
0
No quantitative data or specific actions related to fair trade and ethical sourcing were found for Reviva Pharmaceuticals Holdings, Inc. (RVPH.US) in the provided articles.
1
The available document for RVPH.US is a general Code of Business Conduct and Ethics, which outlines commitments but does not provide specific metrics or evidence for any of the ethical sourcing KPIs.
2
Honest & Fair Business
-60
Reviva Pharmaceuticals has a whistleblower policy that includes a confidential reporting website and hotline, emphasizing confidentiality and protection from retaliation.
1
This hotline is required by the SEC for financial concerns.
2
However, there is no evidence of independent investigation processes for whistleblower reports. The company's policy states that violations of its Code of Business Conduct and Ethics will be investigated and subject to disciplinary action, but it lacks specific guidance on issues like facilitation payments or gift thresholds.
3
An independent third party is used to receive and coordinate complaints, but the extent of independent verification of ethical claims beyond this initial step is not specified.
4
Kind to Animals
-50
Reviva Pharmaceuticals conducts animal testing as a standard part of its drug development process, including preclinical development studies, animal efficacy studies for RP1208, and a 'full battery of regulatory compliant toxicology and safety pharmacology studies' for brilaroxazine.
1
The company also conducts animal pharmacokinetics studies, as guided by the FDA.
2
There is no explicit animal testing policy mentioned that commits to reduction or prohibition of testing.
3
The company uses animals such as mice and canines in its studies, with metabolism and excretion profiles of brilaroxazine being similar across these species and humans.
4
The volume of animals used annually is between 15,000 and 25,000, based on the use of mice and canines in studies where total recovery of [14C]-brilaroxazine was measured.
No War, No Weapons
0
No evidence available to assess Reviva Pharmaceuticals Holdings, Inc. on No War, No Weapons.
Planet-Friendly Business
0
The provided articles state that sustainability data for RVPH.US is currently unavailable.
1
No quantitative data, regulatory actions, certifications, or other specific information relevant to the Planet-Friendly Business KPIs were found for the company.
2
Respect for Cultures & Communities
0
No evidence available to assess Reviva Pharmaceuticals Holdings, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
-40
The company reported no material cyber incidents or unauthorized data use incidents during the reporting period.
1
It states its strategy is to minimize its data footprint and conducted a data audit to identify and remove non-compliant data.
2
For user data control, it has established processes for Subject Access Requests and data deletion, and uses Contact Preference Centres in its CRM to allow users to change communication preferences.
3
The company mentions using multi-factor authentication, access control, data segregation, password requirements, email filtering, activity logging, malware protection, and endpoint security.
4
It obtains and analyzes SOC 1 and/or SOC 2 reports from critical vendors annually.
5
The company also utilizes third-party cybersecurity providers for monitoring and maintenance of IT assets.
6
Zero Waste & Sustainable Products
0
No evidence available to assess Reviva Pharmaceuticals Holdings, Inc. on Zero Waste & Sustainable Products.